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• Retrospective chart review of subjects who received fluphenazine
decanoate, haloperidol decanoate, risperidone microspheres,
aripiprazole extended release, or paliperidone palmitate
• Data was collected from patients between January 2015 – June 2017
• Primary outcome:
• Percentage of patients appropriately prescribed long-acting
injectable antipsychotics according to specified criteria from
each agent’s package insert:
• Approved indication for therapy
• Approved dosing intervals
• Approved dosing
• Approved dosing titrations in applicable patients
• Previous trial with oral antipsychotic(s)
• Age ≥ 18 years
• Renal impairment dose adjustments (if applicable)
• Secondary outcomes:
• Occurrence of behavioral health unit admissions
• Duration of therapy within Parkview EMR

Baseline Characteristics
Mean age (yrs ± SD)
Male (%, n)
Prescribing physician, Psychiatry (%, n)
Patients with ≥ 1 LAI antipsychotic trial (%, n)
Concurrent documented substance abuse (%, n)
Concurrent cognitive impairment (%, n)
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Prescribing Patterns of LAI Antipsychotics

• Many behavioral health facilities in the area focus on injectable agents
in which we do not have access to the EMR. Short durations of
therapy in this study population could be secondary to this lack of
access.
• Paliperidone was the most commonly prescribed LAI antipsychotic in
this subset. This may be due to a prescription assistance program that
qualifies many patients at our institution for cost savings. In addition,
the advantages of this product include longer dosing intervals and no
oral overlap needed compared to the other agents.
• There is an increased risk of experiencing side effects in patients that
receive these agents in shorter dosing intervals than recommended.
Many patients received injections at shorter dosing intervals, which
could be due to patient compliance concerns.
• Patients that did not receive previous trial with an oral antipsychotic
were identified as being prescribed by family medicine practitioners as
opposed to psychiatrists.
• According to the FDA approved package insert, paliperidone requires
previous therapy with oral risperidone or paliperidone only, which led
to low percentage of patients with inadequate oral agent trials for this
medication.
• FDA approved indications for these agents are limited to schizophrenia
and bipolar disorder. Off-label psychiatric conditions (anxiety and
depression) were common other indications for therapy. Literature
supports the use of LAI antipsychotics in treatment-resistant
depression, anxiety, and other mental health disorders. This was not
assessed here and further research is warranted.
• Patients with one or more behavioral health unit hospitalizations was
20.2%. This finding is low compared to previous studies
demonstrating rates of re-hospitalizations > 50%.5
• Limitations
• Retrospective chart data
• Inability to follow majority of patients receiving medications at
other locations
• Impact on Practice
• This study provides evidence to target this high risk population for
care coordination to ensure improved disease outcomes.
• Further emphasis should be placed on pharmacist provided
education to patients regarding the importance of compliance.
• Additionally, a focus on monitoring for side effects in patients that
receive LAI antipsychotics at shorter dosing intervals is
recommended.

Indication

• Patients with schizophrenia and related psychiatric disorders may
exhibit poor adherence.1-4
• Development of long-acting injectable (LAI) antipsychotics address
concerns of poor compliance.1-4
• Previous studies demonstrated patients with concurrent documented
substance abuse and cognitive impairment may be ideal candidates
for long-acting injections.1
• Additionally, previous studies demonstrate benefits in lowering
relapse rates and number of hospitalizations.1-3
• Differences in indications for use, recommendations for oral
antipsychotic overlap, titration instructions, and dosing intervals
provide challenges for prescribing clinicians.1-4
• Improving understanding of appropriate prescribing of LAI
antipsychotics may improve patient outcomes, minimize side effects,
and decrease unnecessary healthcare costs.4
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